RECEIVED **CENTRAL FAX CENTER**

DEC 08 2005

PTO/S8/30 (08-00)

	Appliated for the mindred research arms and an
	U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC
	U.S. Patent and trademark Office. O.S. DEFANTALIS. OF COMMENT
or the Demanustic Reduction Act of 1995, no persons are required to respon	a service of before induce it declare a valid OMB control outth
na the Dananumi, Radurtino Act of 1995, no persons are required to respon	to a collection of inicitization differs it displays a value assessment trains

REQUEST **FOR CONTINUED EXAMINATION**

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.

See The American Inventors Protection Act of 1999 (AIPA).

to respond to a collection of information uni	less it displays a valid OMB control number.
Application Number	10/624,151
Filing Date	July 21, 2003
First Named Inventor	Yaron Keidar
Group Art Unit	3739
Examiner Name	Peter J. Vrettakos
Attorney Docket Number	BIO-5015 NP

This is a	a Request for Continued Examination (RCE) under 37 C.F.H. § 1.114 of the above-dentified application. NOTE: 97 C.F.R. § 1.114 is effective on May 29, 2000. If the above-dentified application was filed prior to http: 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SBZ9) instead of a RCE to be eligible for the patent form adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Apolication Practice, Final Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Oil. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.	
4 Cube	mission required under 37 C.F.R. § 1.114	
	Previously submitted	
a.	i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on	
	(any unentered amendment(s) referred to above will be entered).	
	ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on	
	19 The Advances are enfantesized as an extension of the second of the se	
	ii. Dother	
b.	Enclosed	
	i. Amendment/Reply	
]	ii. Affidavit(s)/Declaration(s)	
]	iii. 🔯 Information Disclosure Statement (IDS)	
	iv. 🔯 Other (Submission Under Mpep609D, Statement)	
2. Misc	celianeous	
Я	Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of	
months.		
b.	C) Other	
3. Fee	s - The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed	
a.	The Director is hereby authorized to charge the following fees, or credit any overpayments,	
"	to Deposit Account No. 10-0750.	
	i. ⊠ RCE fee is required under 37 C.F.R. § 1.17(θ)	
	ii. Extension of Time (37 C.F.R. §§ 1.136 and 1.17)	
	iii. Other	
b.	Check in the amount of \$enclosed	
C.	Payment by credit card (Form PTO-2038 enclosed)	

Name (print/type)	SIGNATURE OF APPLICANT, Vincent J. Serrao	Registration No.	47,072
Signature	/Vincent J. Serrao/ Vincent J. Serrao, Reg. # 47,072	Date	December 8, 2005
-	CERTIFICATE OF R	MAILING OR TRANSMISSION	
I hereby certify	that this paper (along with any paper	referred to as being attache	ed or enclosed) is being facsimile 3300.
transmitted to the	that this paper (along with any paper ne United States Patent and Trademan nt J. Serrao	referred to as being attache	ed or enclosed) is being facsimile 3300. December 8, 2005
transmitted to the Vince	ne United States Patent and Trademan	referred to as being attached Office, Fax No. (571) 273-	3300.

790.00 DA